The Women’s Health Initiative Memory Study (WHIMS) has prompted a reevaluation of menopause hormone therapy (MHT) and its implications for brain health. Initially, findings from the early 2000s suggested that MHT increased risks for heart disease, stroke, breast cancer, and dementia, leading to a decline in its use. However, recent analyses indicate that timing and type of MHT are critical factors influencing outcomes, particularly regarding cognitive health.

Experts now recognize that starting MHT around the time of menopause may offer benefits for brain health, while initiating treatment later could be linked to increased dementia risk. Additionally, not all MHT formulations are equal; variations in hormone types and delivery methods can significantly impact health outcomes. This nuanced understanding is reshaping the conversation around MHT, moving away from a one-size-fits-all approach to a more personalized strategy.

For longevity professionals, the key takeaway is that MHT, when tailored to individual needs and initiated at the appropriate time, may play a role in supporting healthy brain aging, underscoring the importance of ongoing research in this area.

Source: superagingnews.com